IDH1 and central nervous system cancer: Gliomas harboring isocitrate dehydrogenase 1 (IDH1) mutations [9] have been reported to have a decreased ability to compensate for reactive oxygen species (ROS) [10], due to reduced IDH1‐wild‐type activity and concomitant low NADPH [11, 12].